Tucker Asset Management LLC Has $563,000 Position in Pfizer Inc. (NYSE:PFE)

Tucker Asset Management LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,546 shares of the biopharmaceutical company’s stock after buying an additional 476 shares during the period. Tucker Asset Management LLC’s holdings in Pfizer were worth $563,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC increased its stake in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in Pfizer in the 4th quarter valued at $32,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the 4th quarter worth about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer during the 4th quarter worth about $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE PFE traded down $0.12 during trading on Friday, reaching $27.53. The company’s stock had a trading volume of 29,461,921 shares, compared to its average volume of 32,712,070. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $156.00 billion, a price-to-earnings ratio of -458.76, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.36. The firm has a 50 day moving average price of $27.56 and a 200 day moving average price of $27.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the previous year, the firm posted $1.23 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.10%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PFE shares. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Guggenheim started coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $35.86.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.